The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multiinstitutional phase II study

Nobukazu Fuwa¹, Takeshi Kodaira², Takashi Daimon³ & Tomokazu Yoshizaki⁴

¹Department of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan
²Department of Radiation Oncology, Aichi Cancer Center, Aichi, Japan
³Department of Biostatistics, Hyogo College of Medicine, Hyogo, Japan
⁴Department of Otorhinolaryngology, Kanazawa University, Ishikawa, Japan

Keywords
5-fluorouracil, alternating chemoradiotherapy, cisplatin, nasopharyngeal carcinoma, phase 2 study

Abstract
To examine the long-term outcomes of alternating chemoradiotherapy (ALCRT) for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to assess the efficacy of ALCRT for NPC. Patients with stage IIB to IVB, ECOG PS 0–2, 18–70 years-old, and sufficient organ function were eligible for this study. First, chemotherapy, consisting of 5-fluorouracil (800 mg/m² per 24 h on days 1–5) and cisplatin (100 mg/m² per 24 h on day 6), was administered, then a wide field of radiotherapy (36 Gy/20 fraction), chemotherapy, a shrinking field of radiotherapy (34 Gy/17 fraction), and chemotherapy were performed alternately. Between December 2003 and March 2006, 90 patients in 25 facilities were enrolled in this study, 87 patients were finally evaluated. A total of 67 patients (76.1%) completed the course of treatment. The overall survival and the progression-free survival rates at 5 years were 78.04% (95% CI: 69.1–87.0%), and 68.74% (95% CI: 58.8–78.7%), respectively. The long-term outcomes of ALCRT for NPC were thought to be promising. ALCRT will be considered to be a controlled trial to compare therapeutic results with those of concurrent chemoradiotherapy for NPC.

Introduction
Nasopharyngeal carcinoma (NPC) is endemic in Southern China and Southeast Asia [1, 2]. However, it is a rare disease in most countries including Japan [3]. Because of anatomical features, NPC is not suitable for surgery. In addition, the majority of NPC which has wild-type p53 is highly radiosensitive [4]. Thus, radiotherapy (RT) plays a central role in the locoregional control of NPC [5, 6]. Another characteristic of NPC is that distant metastasis is more common than it is in other carcinomas of the head and neck. Therefore, chemotherapy plays an important role in improving treatment outcomes.

In 1998, the American Intergroup 0099 study (IGS 0099), which used three courses each of concurrent chemotherapy (cisplatin [CDDP], 100 mg/m²) and adjuvant chemotherapy (AC) (CDDP, 80 mg/m² and 5-fluorouracil [5-FU], 4000 mg/m² per 4 days), was the first study to demonstrate significant improvements in the overall survival (OS) compared with RT alone [7]. However, issues have arisen with this treatment method. A higher incidence of adverse events of Grade 3 or higher has been observed in the chemoradiation group than in the radiation alone group (59% vs. 34%). Approximately, about 55% underwent the full course of AC. As a result, chemotherapy reduced distant metastasis. However, it might not be sufficient.
In the Aichi Cancer Center, we conducted alternating chemoradiotherapy (ALCRT) with three courses of FP (5-FU and CDDP) in patients with locally advanced NPC from 1987 and reported promising results with a better compliance [8, 9]. Considering these results, a phase II study in which 25 facilities participated was initiated in December 2003.

The present study was to evaluate the long-term outcomes and to assess the usefulness of ALCRT in patients with NPC.

**Materials and Methods**

Eligible patient for this study was as follows, histologically-proven WHO type I to III NPC, clinical stage IIB-IVB (2003 TNM), age 18–70 year old with a performance score of 0–2 (Eastern Cooperative Oncology Group), WBC count $\geq 3000/mm^3$, neutrophil $\geq 1500/mm^3$, platelet count $\geq 100,000$ mm$^{-3}$, hemoglobin $\geq 10$ g/dL, total bilirubin $\leq 2.0$ mg/dL, creatinine clearance $\geq 60$ mL/min, without physical and mental diseases that were obstacle to receive the protocol therapy, and approved by the Ethics Committee of each facility.

The patients with active multiple cancer, history of radiotherapy and/or surgery for head and neck cancer, obvious infectious diseases, and history of severe drug allergy, were excluded from registration. Extend of disease evaluation included a fiberscopic examination of upper-airway from nose to hypopharynx, chest X-P, liver ultrasonography or CT, bone scan, computed tomography (CT) scan and magnetic resonance image (MRI) scan of the nasopharynx, skullbase, and neck. All patients were required to provide written informed consent before registration.

**Alternating chemoradiotherapy**

The treatment scheme is shown in Figure 1. 5FU at a dose of 800 mg/m$^2$ per 24 h was administered intravenously for a 120-h infusion, followed by a 24 h infusion of CDDP at a dose of 100 mg/m$^2$ per 24 h (day 6). During the course of ALCRT, chemotherapy was performed before RT, and RT (Field A) was then performed for 4 weeks beginning 2–3 days after the completion of chemotherapy. The second course of chemotherapy was performed 2–3 days after the completion of RT. The second course of RT (Field B) was then performed with a reduced irradiation field 2–3 days after the second chemotherapy. Furthermore, the third course of chemotherapy was performed 2–3 days after the completion of the second course of RT.

Chemotherapy was not performed when serum creatinine levels exceeded 1.5 mg/dL at the scheduled date of chemotherapy. In addition, chemotherapy was postponed for the patients with WBC counts $<3000/mm^2$ or platelet counts $<75,000/mm^2$ at the scheduled date of chemotherapy. Moreover, when the patients did not meet the above hematologic criteria (WBC counts $\geq 3000/mm^2$ and platelet counts $\geq 75,000/mm^2$) more than 6 weeks after the last day of previous chemotherapy, the administration of chemotherapy was abandoned. When the WBC counts were $<1000/mm^2$ or the platelet counts were $<25,000/mm^2$ after chemotherapy, the doses of 5-FU and CDDP were reduced by 25% at the next administration. The doses of CDDP could be reduced by 25% when serum creatinine levels temporarily exceeded 1.5 mg/dL, the dose of the next CDDP administration alone was decreased by 25%.

Using a 6-MV photon beam by linear accelerator, RT was performed with a daily fraction of 1.8 Gy from day 10 to 37 and 2 Gy from day 49 to 71. The initial radiation field covered between the nasopharynx and middle cervical region, using bilateral opposing portals and between lower cervical and supraclavicular regions using the anterior single field irradiation at a dose of 36 Gy/20 fraction. Then, a shrinking field of 34 Gy/17 fraction was boosted to the nasopharynx using the dynamic conformal

---

**Figure 1.** Study design of alternating chemoradiotherapy. 5FU: 5-fluorouracil; 800 mg/m$^2$ per day i.v. continuous infusion × 5 days (day 1–5); CDDP: cisplatin, 100 mg/m$^2$ per day i.v. continuous infusion (day 6); Field A: large field (from the skull base to the supraclavicular fossa), 1.8 Gy/f, 5 f/w, total tumor dose; 36 Gy; Field B: shrinking field, 2 Gy/f, 5 f/w, total tumor dose; 34 Gy. The interval between Field A and Field B is 10–12 days.
rotational technique or bilateral opposing portals. In the cervical lymph nodes in which metastases were detected during the initial examination, 34 Gy of 6-MV photon beam or electron beam in 17 fractions was additionally irradiated (Field B). The dose of irradiation to the spinal cord, optic chiasm, and brain was limited to less than 40 Gy, 48 Gy, and 56 Gy, respectively.

Neck dissection was allowed to be performed on patients with progressive nodal disease or disease persistence.

Patient assessments

According to the National Cancer Institute-Common Toxicity Criteria ver. 3.0, the toxicity of this ALCRT was evaluated. The antitumor effects of were evaluated 1 month after the completion of this treatment, according to the Response Evaluation Criteria in Solid Tumors (RECIST).

Patients were assessed every 2 months during the first year, every 3 months for the subsequent 2 years, and every 4–6 months thereafter. Locoregional recurrences were assessed by physical examination, fibrescopic examination, biopsy, and MRI and/or CT. Distant metastases were assessed by chest X-P, liver ultrasonography or CT, and bone scan.

Continuous and categorical variables are presented as medians with ranges and as frequencies with percentages, respectively. OS, progression-free survival (PFS), locoregional recurrence-free (LRF), and distant metastasis-free (DMF) curves were estimated using the Kaplan–Meier method. In univariate analysis, potential factors associated with each of OS, PFS, LRF, and DMF were explored using the log-rank test. In multivariate analysis, the factors that were found to have values of $P < 0.1$ in the log-rank test were included in the Cox proportional-hazards regression model. The results are summarized as hazard ratios, 95% confidence intervals, and $P$-values, based on the Cox regression. All $P$ values were two-sided, and $P < 0.05$ was considered statistically significant. Statistical analyses were performed using R (version 3.1.1, Vienna, Austria).

Results

Ninety eligible patients with NPC were enrolled in this study between December 2003 and March 2006, and 88 patients were finally enrolled, excluding two patients with heart disease and patient refusal. Furthermore, distant metastasis was diagnosed in one patient with the imaging performed during the first chemotherapy, and this patient underwent treatment, according to the protocol. We then evaluated the adverse effects in these 88 patients and the tumor response and survival periods in 87 patients, excluding the distant metastasis case. The patient characteristics were shown in Table 1.

Thirteen patients (14.8%) discontinued treatment for the following reasons: unable to continue treatment due to deterioration in the general physical condition (three patients), patient refusal (five patients), responsible physician’s judgment (four patients), and unknown (one patient). Patients were considered to have completed the course of treatment if they were administered at least 70% of both the medication and radiological doses. As a result, a total of 80 patients (91%) completed the radiation therapy, and a total of 67 patients (76.1%) completed the course of treatment. The total tumor dose ranged from 36 to 76 Gy (median: 70 Gy, mean: 69.38 Gy) in the nasopharynx and from 36 to 76 Gy (median: 66 Gy, mean: 64.28 Gy) in the metastatic cervical lymph nodes. The total 5-FU dose ranged from 3380 to 12,669 mg/m$^2$ (median: 12,000 mg/m$^2$, mean: 10,800 mg/m$^2$), and the total CDDP dose ranged from 100 to 306 mg/m$^2$ (median: 300 mg/m$^2$, mean: 267.5 mg/m$^2$). Furthermore, the total duration of RT ranged from 35 to 127 days (median: 66 days), and the overall treatment time (OTT) of ALCRT ranged from 7 to 114 days (median: 87 days). The median follow-up duration for all

### Table 1. Patient characteristics.

| Characteristic | Number of patients (%) |
|----------------|------------------------|
| Performance status |                      |
| 0              | 74 (84.1)              |
| 1              | 12 (13.6)              |
| 2              | 2 (2.3)                |
| Gender         |                        |
| Male           | 67 (76.1)              |
| Female         | 21 (23.9)              |
| Stage          |                        |
| II B           | 22 (25.0)              |
| III T1N1M0: 11, T2aN1M0: 5, T2bN1M0: 6 | 36 (40.9) |
| III T1N2M0: 13, T2bN2M0: 9, T3N0M0: 3 T3N1M0: 2, T3N2M0: 9 | 16 (18.2) |
| IV A T4N0M0: 3, T4N1M0: 3, T4N2M0: 10 | 13 (14.8) |
| IV B T1N3M0: 6, T2aN3M0: 1, T2bN3M0: 1 T3N3M0: 2, T4N3M0: 3 | 1 (1.1) |
| IV C T3N2M1: 1 |                        |
| Histology      |                        |
| WHO type I     | 18 (20.5)              |
| WHO type II    | 32 (36.4)              |
| WHO type III   | 38 (43.2)              |
88 patients was 67 months (range: 3–91 months) by March 2012.

Toxicity

The acute toxicities were shown in Table 2. The major acute adverse effects of >Grade 3 were as follows: anorexia in 42 patients (47.7%), leukocytopenia in 40 patients (45.5%), and mucositis in 28 patients (31.8%).

The main late toxicities were shown in Table 3. The late adverse effects of >Grade 2 were as follows: dry mouth in 32 patients (36.3%), mucosal damage in 9 patients (10.2%), cervical cellulitis in 1 patient (1.1%), infection of the middle ear in 1 patient, and hearing loss in 1 patient.

Treatment outcome

A complete response was achieved in 54 patients (62.0%), a partial response in 26 patients (29.9%), a stable disease in 4 patients, and an unknown in 2 patients. The initial recurrent sites were the nasopharynx in 12 patients, the regional lymph nodes in 3 patients, and distant metastasis in 12 patients. Table 4 shows the initial recurrent sites, according to the histopathological findings.

Table 2. Acute adverse effects.

| Toxicity grade (number of patients), n = 88 | 0 | 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|
| Toxicity | 0 | 1 | 2 | 3 | 4 |
| Hematologic | | | | | |
| White blood cell | 3 | 9 | 36 | 38 | 2 |
| Neutrophil | 22 | 9 | 37 | 20 | 0 |
| Platelet | 31 | 35 | 18 | 5 | 2 |
| Hemoglobin | 7 | 32 | 32 | 12 | 5 |
| GOT | 52 | 30 | 5 | 1 | 0 |
| GPT | 33 | 44 | 10 | 1 | 0 |
| Creatinine | 52 | 24 | 12 | 0 | 0 |
| Nonhematologic | | | | | |
| Allergic reaction | 84 | 1 | 3 | 0 | 0 |
| Hearing | 77 | 0 | 9 | 2 | 0 |
| Fever | 81 | 0 | 3 | 4 | 0 |
| Infection | 4 | 15 | 35 | 28 | 5 |
| Loss of hair | 55 | 32 | 1 | 0 | 0 |
| Anorexia | 7 | 18 | 20 | 42 | 0 |
| Diarrhea | 62 | 9 | 15 | 2 | 0 |
| Dry mouth | 25 | 27 | 23 | 13 | 0 |
| Mucositis | 12 | 14 | 34 | 28 | 0 |
| Nausea | 4 | 22 | 39 | 23 | 0 |
| Vomiting | 33 | 16 | 29 | 10 | 0 |
| Neurological disorder | 86 | 1 | 0 | 0 | 0 |

Until March 2012, 61 patients (70.1%) were alive, and 59 of these 61 remain cancer free. Twelve patients died of local recurrence, 12 patients died of distant metastases, and 2 patients died of unrelated causes without cancer. The OS and PFS curves are shown in Figure 2. The 5 year OS and PFS rates were estimated to be 78.04% (95% CI, 69.1–87.0%) and 68.74% (95% CI, 58.8–78.7%), respectively.

Factors involved in the overall survival and progression-free survival time (Tables 5, 6)

In the univariate analysis, N classification and total 5-FU dose had significant impacts on OS. In the multivariate analysis, N classification had a significant impact on OS.

In the univariate analysis, gender, N classification, total 5-FU dose, and total CDDP dose had significant impacts on PFS. In the multivariate analysis, gender and N classification had significant impacts on PFS.

Factors involved in the locoregional recurrence-free and distant metastasis-free rates (Tables 7, 8)

The LRF and DMF curves are shown in Figure 3. In the univariate analysis, gender, T classification, and WHO histological classification had significant impacts on the LRF rate. In the multivariate analysis, the WHO histological classification and radiation dose in the nasopharynx had significant impacts on LRF rate.

In the univariate analysis, N classification, stage, and total CDDP dose had significant impacts on the DMF rate. In the multivariate analysis, stage, total CDDP dose, N classification, and WHO histological classification had significant impacts on the DMF rate.
IGS 0099 was considered a landmark for NPC treatment [7]. However, 3 courses of AC were administered after concurrent chemoradiotherapy (CCRT) in 55% of the patients. The objective of chemotherapy in NPC treatment is not only the improvement of local control but also the control of micrometastasis. In particular, the main role of AC is to control the latter, that is, distant metastasis. An analysis that combined data from NPC 9901 and NPC 9902, large-scale clinical trials involving the same treatment method as that outlined in IGS 0099, has indicated that AC was a factor related to the control of distant metastasis and that a particular correlation was noted with the 5-FU dose. When compared with 260 patients who received 0–1 cycle of adjuvant cycles, significant improvement was achieved in 167 patients with 3–4 cycles (P = 0.019) [10]. A meta-analysis also found that the involvement of CCRT in the control of distant metastasis was marginal (P = 0.04), but AC was a factor that exhibited a significant involvement (P = 0.009) [11]. In accordance, AC has been shown to be involved in the decrease of distant metastasis, but the results of a randomized controlled trial (RCT) comparing the treatment outcomes between a CCRT + AC group and a CCRT group and the results of a meta-analysis have not demonstrated any improvements in survival rates by the addition of AC [12, 13].

It has been proved that acute toxicity caused by CCRT reduces tolerance to AC, and neoadjuvant chemotherapy (NAC) + CCRT may be one future direction for treatment. Boscolo et al. reported the favorable long-term retrospective outcome after NAC+CCRT for locally advanced NPC [14]. In 2009, Hui et al. divided subjects into a group that underwent NAC involving 2 courses of CDDP (75 mg/m²) and docetaxel (75 mg/m²) every 3 weeks before undergoing CDDP (40 mg/m²) weekly as CCRT and a group that underwent CCRT with the same method. They compared these groups in a randomized phase II study and found that the 3-year OS rates were 94.1% and 67.7% for each group, respectively, and the 3-year PFS rates were 88.2% and 59.5%, respectively, indicating favorable outcomes for the NAC + CCRT group [15]. However, in 2013, Liang et al. conducted 11 RCTs comparing groups that underwent CCRT after NAC with those that underwent CCRT (with or without AC) in 1096 patients in a meta-analysis and found that PFS was improved, but no differences were observed for OS, loco-regional failure-, and DMF survival [16]. Taxane (docetaxel or paclitaxel) has been confirmed in a meta-analysis.
as an effective medication for NAC in patients with advanced carcinomas of the head and neck [17]. In 7 of the 11 above-mentioned RCTs, taxane was used. These findings suggest that NAC increases the repopulation of the tumor and a buildup of chemoresistant tumor cells, resulting in decreased therapeutic results in CCRT [18].

Table 5. Results of the univariate analysis of prognostic factors on overall and progression-free survival.

| Factor         | Level (n) | Overall survival | Progression-free survival |
|----------------|-----------|------------------|---------------------------|
|                |           | Univariate analysis |                           |
|                |           | HR¹  | 95% CI | P-value | HR¹  | 95% CI | P-value |
| Age            | <50 (36)  | 1    | 0.732–3.476 | 0.5097 | 1    | 0.582–2.826 | 0.5368 |
|                | ≥50 (60)  | 1.367 |          |        | 1.282 |          |        |
| Gender         | Male (66) | 1    | 0.732–3.476 | 0.0937 | 1    | 0.049–0.873 | 0.0176 |
|                | Female (21) | 0.306 |          |        | 0.206 |          |        |
| TNM primary    | 1 or 2 (52) | 1    | 0.463–2.866 | 0.7609 | 1    | 0.913–4.272 | 0.0781 |
|                | 3 or 4 (35) | 1.159 |          |        | 1.975 |          |        |
| TNM LN         | 0 or 1 (33) | 1    | 1.688–94.785 | 0.0014 | 1    | 2.124–38.12 | 0.0003 |
|                | 2 or 3 (54) | 12.647 |          |        | 8.998 |          |        |
| Stage          | II or III (58) | 1    | 0.6103–3.779 | 0.3656 | 1    | 0.878–4.110 | 0.0975 |
|                | IV (29) | 1.518 |          |        | 1.900 |          |        |
| WHO pathology  | I (18) | 1    | 0.301–2.745 | 0.8669 | 1    | 0.305–1.895 | 0.556 |
|                | II or III (69) | 0.910 |          |        | 0.761 |          |        |
| PS             | 0 (73) | 1    | 0.125–2.370 | 0.4109 | 1    | 0.470–3.3090 | 0.6561 |
|                | 1 or 2 (14) | 0.545 |          |        | 1.248 |          |        |
| RT dose primary| <70 (5) | 1    | 0.1518–8.583 | 0.8989 | 1    | 0.172–3.84 | 0.6654 |
|                | ≥70 (81) | 1.1140 |          |        | 0.728 |          |        |
| RT dose lymph node | <70 (21) | 1    | 0.591–11.072 | 0.1927 | 1    | 0.504–3.545 | 0.5585 |
|                | ≥70 (65) | 2.558 |          |        | 1.337 |          |        |
| Total dose of 5-FU | <12,000 (37) | 1 | 0.140–0.903 | 0.0230 | 1    | 0.162–0.789 | 0.0078 |
|                | ≥12,000 (50) | 0.355 |          |        | 0.357 |          |        |
| Total dose of CDDP | <300 (38) | 1    | 0.232–1.411 | 0.4560 | 1    | 0.205–0.974 | 0.0375 |
|                | ≥300 (49) | 0.573 |          |        | 0.447 |          |        |
| OTT²           | <87 (38) | 1    | 0.191–1.273 | 0.1361 | 1    | 0.261–1.2691 | 0.1656 |
|                | ≥87 (47) | 0.494 |          |        | 0.576 |          |        |

¹Hazard ratio.
²Overall treatment time.

Table 6. Results of the multivariate analysis of prognostic factors on overall and progression-free survival.

| Factor         | Level (n) | Overall survival | Progression-free survival |
|----------------|-----------|------------------|---------------------------|
|                |           | Multivariate analysis |                           |
|                |           | HR¹  | 95% CI | P-value | HR¹  | 95% CI | P-value |
| Gender         | Male (66) | 1    | 0.074–1.404 | 0.1316 | 1    | 0.049–0.910 | 0.0369 |
|                | Female (21) | 0.322 |          |        | 0.211 |          |        |
| TNM primary    | 1 or 2 (52) | 1    | 1.765 |          |        | 0.781–3.985 | 0.1741 |
|                | 3 or 4 (35) | 10.267 |          |        | 1.453–27.946 | 0.0141 |
| TNM LN         | 0 or 1 (33) | 1    | 6.372 |          |        | 1.453–27.946 | 0.0141 |
|                | 2 or 3 (54) | 0.296 |          |        | 0.198 |          |        |
| Stage          | II or III (58) | 1    | 0.517–2.774 | 0.6734 | 1    | 1.198 |          |        |
|                | IV (29) | 1.198 |          |        | 0.6734 |          |        |
| Total dose of 5-FU | <12,000 (37) | 1 | 0.0531 |          |        | 0.406 |          |        |
|                | ≥12,000 (50) | 0.396 |          |        | 1.62–1.015 | 0.539 |
| Total dose of CDDP | <300 (38) | 1    | 0.358–2.181 | 0.7889 | 1    | 0.848 |          |        |
|                | ≥300 (49) | 1.884 |          |        | 0.7889 |          |        |

¹Hazard ratio.

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

1191
### Table 7. Results of the univariate analysis of prognostic factors on locoregional and distant metastasis-free rates.

| Factor                     | Level (n) | Locoregional-free rate | Distant metastasis-free rate |
|----------------------------|-----------|------------------------|------------------------------|
|                            |           | Univariate analysis    |                              |
|                            |           | HR ¹ | 95% CI       | P-value | HR ¹ | 95% CI       | P-value |
| Age                        | <50 (36)  | 1    | 0.4715–5.200 | 0.4604  | 1    | 0.330–3.278 | 0.9462  |
|                           | ≥50 (50)  | 1.566| 0.4715–5.200 | 0.4604  | 1    | 0.330–3.278 | 0.9462  |
| Gender                     | Male (66) | 1    | 0              | 0.0303  | 1    | 0              | 0.0303  |
|                           | Female (21) |   | 0              | 0.0303  | 1    | 0              | 0.0303  |
| TNM primary                | 1 or 2 (52) | 1    | 0.956–10.548  | 0.0464  | 1    | 0.492–4.735  | 0.4602  |
|                           | 3 or 4 (35) | 3.175| 0.956–10.548  | 0.0464  | 1    | 0.492–4.735  | 0.4602  |
| TNM LN                     | 0 or 1 (23) | 1    | 0.761–15.925  | 0.0866  | 1    | 0              | 0.0032  |
|                           | 2 or 3 (54) | 3.482| 0.761–15.925  | 0.0866  | 1    | 0              | 0.0032  |
| Stage                      | IIb or III (58) | 1    | 0.318–3.518  | 0.9262  | 1    | 1.390–15.379 | 0.0060  |
|                           | IV (29)   | 1.058| 0.318–3.518  | 0.9262  | 1    | 1.390–15.379 | 0.0060  |
| WHO pathology              | I (18)    | 1    | 0.099–0.986  | 0.0359  | 1    | 0              | 0.0850  |
|                           | II or III (69) | 0.312| 0.099–0.986  | 0.0359  | 1    | 0              | 0.0850  |
| PS                         | 0 (73)    | 1    | 0.476–6.503  | 0.3902  | 1    | 0.252–5.250  | 0.8572  |
|                           | 1 or 2 (14) | 1.760| 0.476–6.503  | 0.3902  | 1    | 0.252–5.250  | 0.8572  |
| RT dose primary            | <70 (5)   | 1    | 0.064–1.340  | 0.9242  | 1    | 0              | 0.4078  |
|                           | ≥70 (81)  | 0.293| 0.064–1.340  | 0.9242  | 1    | 0              | 0.4078  |
| RT dose LN                 | <70 (21)  | 1    | 0.254–3.471  | 0.9255  | 1    | 0.356–7.407  | 0.5279  |
|                           | ≥70 (65)  | 0.940| 0.254–3.471  | 0.9255  | 1    | 0.356–7.407  | 0.5279  |
| Total dose of 5-FU         | <12,000 (37) | 1    | 0.135–1.349  | 0.1354  | 1    | 0.143–1.429  | 0.1657  |
|                           | ≥12,000 (50) | 0.427| 0.135–1.349  | 0.1354  | 1    | 0.143–1.429  | 0.1657  |
| Total dose of CDDP         | <300 (38) | 1    | 0.210–2.024  | 0.4560  | 1    | 0.096–1.060  | 0.0490  |
|                           | ≥300 (49) | 0.652| 0.210–2.024  | 0.4560  | 1    | 0.096–1.060  | 0.0490  |
| OTT¹                       | <87 (38)  | 1    | 0.126–1.474  | 0.1673  | 1    | 0.238–2.291  | 0.5986  |
|                           | ≥87 (47)  | 0.431| 0.126–1.474  | 0.1673  | 1    | 0.238–2.291  | 0.5986  |

¹Hazard ratio.

### Table 8. Results of the multivariate analysis of prognostic factors on locoregional and distant metastasis-free rates.

| Factor                     | Level (n) | Locoregional-free rate | Distant metastasis-free rate |
|----------------------------|-----------|------------------------|------------------------------|
|                            |           | Multivariate analysis  |                              |
|                            |           | HR ¹ | 95% CI       | P-value | HR ¹ | 95% CI       | P-value |
| TNM primary                | 1 or 2 (52) | 1    | 0.897–10.370 | 0.0740  | 1    | 1.549–17.347 | 0.0076  |
|                           | 3 or 4 (35) | 3.051| 0.897–10.370 | 0.0740  | 1    | 1.549–17.347 | 0.0076  |
| TNM LN                     | 0 or 1 (33) | 1    | 0.531–11.913 | 0.2454  | 2    |                            | 0.0076  |
|                           | 2 or 3 (54) | 2.514| 0.531–11.913 | 0.2454  | 2    |                            | 0.0076  |
| Stage                      | IIb or III (58) | 1    | 0.074–0.901  | 0.0336  | 3    |                            | 0.0076  |
|                           | IV (29)   | 0.258| 0.074–0.901  | 0.0336  | 3    |                            | 0.0076  |
| WHO pathology              | I (18)    | 1    | 0.074–0.901  | 0.0336  | 3    |                            | 0.0076  |
|                           | II or III (69) | 0.258| 0.074–0.901  | 0.0336  | 3    |                            | 0.0076  |
| RT dose primary            | <70 (21)  | 1    | 0.035–0.972  | 0.0463  | 3    |                            | 0.0076  |
|                           | ≥70 (65)  | 0.183| 0.035–0.972  | 0.0463  | 3    |                            | 0.0076  |
| Total dose of 5-FU         | <12,000 (37) | 1    | 0.135–1.349  | 0.1354  | 2    |                            | 0.0076  |
|                           | ≥12,000 (50) | 0.427| 0.135–1.349  | 0.1354  | 2    |                            | 0.0076  |
| Total dose of CDDP         | <300 (38) | 1    | 0.210–2.024  | 0.4560  | 1    | 0.096–1.060  | 0.0490  |
|                           | ≥300 (49) | 0.652| 0.210–2.024  | 0.4560  | 1    | 0.096–1.060  | 0.0490  |

Gender was not incorporated into the multivariate analysis because no events were observed in female.

¹Hazard ratio.

²N classification was not incorporated into the multivariate analysis because no events were observed in N0 or N1 patients.

³WHO histology classification was not incorporated into the multivariate analysis because no events were observed in WHO type I patients.
At present, it is clear that CCRT improves the survival rates more than RT alone [12, 19]. The addition of AC after CCRT does not lead to a greater improvement in the survival rates compared with CCRT without AC [12, 13]. It is unclear whether the addition of NAC to CCRT improves survival rates compared with CCRT alone.

Compared with other carcinomas of the head and neck, NPC has high potential of distant metastasis [2]. Insufficient dose chemotherapy has not shown a benefit of control of distant metastasis compared with RT alone, which was suggested in Chan’s study (RT concurrently with cisplatin at a dose of 40 mg/m² weekly, \( P = 0.15 \)) [20]. It is characteristic in NPC that a wider irradiation field is required during RT due to its progression pattern, and mucositis is a marked problem even when RT alone is performed. Considering these characteristics of NPC, ALCRT has two advantages compared with CCRT; a sufficient amount of antitumor agents can be administered to control distant metastasis, and it has the potential benefit in reducing acute toxicities [7, 9].

In Japan, the proportion of patients with WHO type I histopathology is approximately 20%, which is similar to that in North America and much higher than the rates in studies conducted in endemic regions [21]. It has proved to be less sensitive to RT and a significantly worse prognostic factor of OS and PFS [21, 22].

The ALCRT that we administered in the present study led to a 76% treatment completion rate, 78% 5-year OS, and 69% 5-year PFS. Compared with IGS 0099, the ALCRT was advantageous in these followings; a decreased total dose of CDDP (540 mg/m² vs. 300 mg/m²), a shorter treatment period (130 days vs. 87 days), a higher treatment completion rate (53% vs. 76%), and a higher survival rate (78% 3y-OS in IGS 0099 vs. 78% 5y-OS in this study, 69% 3y-PFS in IGS 0099 vs. 69% 5y-PFS in this study). Considering that the percentage of patients classified as WHO type I, indicating a poor outcome, was 21%, the above-mentioned treatment outcomes appear to be extremely favorable.

The present study found that WHO type I histopathology recurred in 6 of the 18 patients, and that recurrence occurred from the irradiation field in all the patients. Therefore, as shown in Table 4, in order to improve the local control rate, a higher dose RT in the form of intensity-modulated RT (IMRT) which is helpful for improving clinical results is necessary, especially for patients who exhibit WHO type I histopathology [23]. Recurrence occurred in 20 of the 69 patients who exhibited WHO type II and III histopathology. Twelve of these patients exhibited distant metastasis, suggesting the necessity of a stronger anti-cancer drug treatment or the combined use of molecular targeted therapy.

Conclusions

This method of ALCRT yielded higher or at least similar survival rates and lower toxicities compared with CCRT. The future direction of ALCRT appears likely to involve the introduction of IMRT, and concerning anti-cancer drugs, the addition of taxane to conventional FP. We
believe that ALCRT will be used in a controlled trial to compare therapeutic results with those of CCRT (with or without NAC).

**Acknowledgments**

The authors appreciate the kind cooperation from the following institutes: Kyoto Prefectural University, Tokushima University, Nara Medical University, Ryukyu University, Kurume University, Kumamoto University, Mie University, Gunma University, Kure Medical Center, Hokkaido Cancer Center, Toyama University, Nihon University, St. Marianna University, Nihon Medical University, Nagoya University, Yamanashi University, Yamaguchi University, Miyagi Cancer Center, Tochigi Cancer Center, Shimane University, Yokohama City University, Ehime University and Kanazawa Medical University. This study was supported by the Grant-Aided Cancer Center, Shimane University, Yokohama City University, Nagoya University, Yamanashi University, Yamaguchi University, Miyagi Cancer Center, Tochigi Cancer Center, Shimane University, Yokohama City University, Ehime University and Kanazawa Medical University. This study was supported by the Grant-Aided Cancer Research (14-15), Ministry of Health, Labor and Welfare of Japan and Translational Research Informatics Center, Kobe.

**Conflict of Interest**

All the authors disclosed no conflicts of interest.

**References**

1. Ho, J. H. C. 1978. An epidemiological and clinical study of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 4:183–197.
2. Wang, D. C., W. M. Cai, and V. C. Hu. 1988. Long term survival of 1035 cases of nasopharyngeal carcinoma. Cancer 61:2328–2341.
3. Curado, M. P., B. Edwards, H.R. shin, H. storm, J. Ferlay, M. Heanue, and P. Boyle, eds. 2007. Cancer incidence in five continents, Vol. 9. IARC Scientific Publications No. 160, International Agency for Research on Cancer. Lyon, France.
4. Xie, X., H. Wang, H. Jin, S. Ouyang, J. Zhou, J. Hu, et al. 2013. Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. Radiat. Oncol. 8:117.
5. Mesic, J. B., G. H. Fletcher, and H. Goepfert. 1981. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 7: 447–453.
6. Wang, C. C., and J. E. Meyer. 1971. Radiotherapeutic management of the carcinoma of the nasopharynx. Analysis of 170 patients. Cancer 28:566–570.
7. Al-Sarraf, M., M. LeBlanc, P. G. Giri, K. K. Fu, J. Cooper, T. Vuong, et al. 1998. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup Study 0099. J. Clin. Oncol. 16:1310–1317.
8. Fuwa, N., Y. Ito, T. Kodaira, A. Matsumoto, M. Kamata, K. Furutani, et al. 2001. Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: its usefulness and controversial points. Jpn. J. Clin. Oncol. 31:589–595.
9. Fuwa, N., Y. Ito, T. Kodaira, A. Matsumoto, M. Kamata, K. Furutani, et al. 2007. Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil. A phase II study. Oral Oncol. 43:948–955.
10. Lee, A. W., S. Y. Tung, R. K. Ngan, R. Chappell, D. T. Chua, T. X. Lu, et al. 2011. Factors contributing to the efficacy of concurrent adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur. J. Cancer 47:656–666.
11. Zhang, L., C. Zhao, B. Ghimire, M. H. Hong, Q. Liu, Y. Zhang, et al. 2010. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 15:558.
12. Chen, L., C. S. Hu, X. Z. Chen, G. Q. Hu, Z. B. Cheng, Y. Sun, et al. 2012. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomized controlled trial. Lancet Oncol. 13:163–171.
13. Liang, Z. G., X. D. Zhu, Z. R. Zhou, S. Qu, Y. Q. Du, Y. M. Jiang, et al. 2012. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials. BMC Cancer 15:1317.
14. Boscolo-Rizzo, P., G. Tirelli, M. Mantovani, V. Baggio, V. Lupato, G. Spinato, et al. 2014. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice. Eur. Arch. Otorhinolaryngol. 2014 Nov 4. [Epub ahead of print] PMID: 25367705.
15. Hui, E. P., B. B. Ma, S. F. Leung, A. D. King, F. Mo, M. K. Kam, et al. 2009. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27:242–249.
16. Liang, Z. G., X. D. Zhu, A. H. Tan, Y. M. Jiang, S. Qu, F. Su, et al. 2013. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal cancer: Phase III randomized Intergroup Study 0099. J. Clin. Oncol. 16:1310–1317.
carcinoma: meta-analysis of 1,096 patients from 11 randomized controlled trials. Asian Pac. J. Cancer Prev. 14:515–521.

17. Blanchard, P., J. Bourhis, B. Lacas, M. R. Posner, J. B. Vermorken, J. J. Hernandez, et al. 2013. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J. Clin. Oncol. 31:2854–2860.

18. John, M. J., M. S. Flam, S. S. Legha, and T. L. Phillips. 1993. Chemoradiation: An Integrated Approach to Cancer Treatment. Lea & Febiger, Philadelphia.

19. Langendijk, J. A., C. R. Leemans, J. Buter, et al. 2004. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J. Clin. Oncol. 22:4604–4612.

20. Chan, A. T., S. F. Leung, R. K. Ngan, P. M. Teo, W. H. Lau, W. H. Kwan, et al. 2005. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 97:536–539.

21. Kawashima, M., N. Fuwa, M. Myojin, K. Nakamura, T. Toita, S. Saijo, et al. 2004. A multi-institutional survey of the effectiveness of chemotherapy combined with radiotherapy for patients with nasopharyngeal carcinoma. Jpn. J. Clin. Oncol. 34:569–583.

22. Ou, S. H., J. A. Zell, A. Ziogas, and H. Anton-Culver. 2007. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann. Oncol. 18:29–35.

23. Lee, N., J. Harris, A. S. Garden, W. Straube, B. Glisson, P. Xia, et al. 2009. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J. Clin. Oncol. 27:3784–3790.